

Optimizing Outcomes in *ALK-Positive NSCLC*

Impact of New Paradigms **CPD**

Medscape®
LIVE!

THURSDAY, 11 APRIL, 2019

TIME: 18:00 – 19:00

VENUE: PALEXPO, GENEVA, SWITZERLAND

LOCATION: ROOM C

MODERATOR

Solange Peters, MD, PhD
Head Physician
Centre Hospitalier Universitaire
Vaudois (CHUV)
Oncology Department
Lausanne, Switzerland

PANELISTS

Raffaele Califano, MD, PhD
Consultant in Medical Oncology
The Christie and University
Hospital of South Manchester
Manchester, United Kingdom

Marina Chiara Garassino, MD, PhD
Medical Consultant
Medical Oncology Division
Fondazione IRCCS
Istituto Nazionale dei Tumori
Milano, Italy

AGENDA

17:45

Light Refreshments

18:00

Welcome and Introduction

Solange Peters, MD, PhD

18:05

***Testing for ALK-Positive Disease:
The State of the Art***

Raffaele Califano, MD, PhD

18:20

***The Expanding Treatment Armamentarium
in ALK-Positive NSCLC: The Evidence***

Marina Chiara Garassino, MD, PhD

18:35

***Case Challenges From the Real-World:
Expert Insights and Future Perspectives
Case 1: Considerations for First-Line
Treatment Selection***

Marina Chiara Garassino, MD, PhD

***Case 2: How Do We Choose a Second-Line
Treatment?***

Raffaele Califano, MD, PhD

18:55

Conclusions and Key Points

Solange Peters, MD, PhD